text.skipToContent text.skipToNavigation

QuantiFERON-TB Gold (QFT) Kit

An aid to the detection of Mycobacterium tuberculosis (TB) infection (1)
  • Accurate and unaffected by prior BCG vaccination (2–4)
  • Efficient, with results after one patient visit (1) 
  • Objective results (1) 
  • Proven performance in immunosuppressed patients (5–8)
QuantiFERON-TB Gold is an in vitro diagnotic test that aids in the detection of infection with M. tuberculosis. QFT is an interferon γ (IFNγ) release assay, also known as an IGRA, which measures the cell-mediated response to specific TB antigens in whole blood.
Cat No./ID: 0594-0201-CA
QuantiFERON-TB Gold 2 Plate Kit ELISA

For 192 preparations, includes: Microplate Strips; Human IFNγ Standard, lyophilized; Green Diluent; Conjugate 100x Concentrate, lyophilized; Wash Buffer 20x Concentrate; Enzyme Substrate Solution; Enzyme Stopping Solution

Cat No./ID: T0590-0301
QuantiFERON-TB Gold (QFT) Tubes (300)
For drawing blood, including 100 Nil, 100 TB Antigen, and 100 Mitogen tubes
Cat No./ID: T0590-0505
QuantiFERON-TB Gold (QFT) High Altitude (HA) Tubes (300)
For drawing blood, including 100 Nil, 100 TB Antigen, and 100 Mitogen HA tubes
Cat No./ID: T0597-0403
QFT Dispenser Pack (4 cartons)

For drawing blood, dispenser pack of QFT tubes in 25 packs per carton, each pack including: 1 Nil tube, 1 TB Antigen tube, and 1 Mitogen tube with Package Insert

The QuantiFERON-TB Gold (QFT) Kit is intended for in vitro diagnostic use.


Diagnosing or excluding TB disease, and assessing the probability of latent TB infection (LTBI), requires a combination of epidemiological, historical, medical, and diagnostic findings that should be taken into account when interpreting a QFT result.
 
References:
  1. QFT Package Insert, March 2013, US05990301L.
  2. Diel, R. et al (2011) Am. J. Respir. Crit. Care Med. 183, 88.
  3. Harada, N. et al. (2008) J. Infect. 56, 348.
  4. Diel, R. et al. (2008) Am. J. Respir. Crit. Care Med. 177, 1164.
  5. Cheallaigh, et al. (2013) PlOs One 8, e53330.
  6. Hoffmann, et al. (2010) Eur. Infect. Dis. 56, 230.
  7. Kwakernaak, A.J. et al. (2011) Clin. Rhuematol. 30, 505.
  8. Pratt, A. et al. (2007) Rheumatology 46, 1035.
  9. Dye, C. et al. (2008) J.R. Soc. Interface 23, 653.
  10. Nienhaus, A., et al. (2008) Int. Arch. Occup. Environ. Health 81, 295.

0
QuantiFERON-TB Gold interpretation flowchart 1
Interpretation flowchart when Nil and TB Antigen tubes are used.
1
QuantiFERON-TB Gold interpretation flowchart 2
Interpretation flowchart when Nil, TB Antigen, and Mitogen tubes are used. 
2
QuantiFERON-TB Gold tubes
QuantiFERON-TB Gold tubes are available for normal altitudes and high altitudes
Performance

Tuberculosis (TB) remains a significant threat to humanity, and therefore identifying TB infection is essential. A person infected with Mycobacterium tuberculosis, but who shows no symptoms is regarded as having latent TB infection. Global organizations acknowledge that to fight TB effectively, accurate identification and treatment of latent TB infection, as well as active TB disease, are vital (9).

QuantiFERON-TB Gold (QFT) is a modern alternative to the 110 year old tuberculin skin test (or Mantoux test) and is the most studied IGRA, with over 800 published peer-reviewed publications. The test is highly accurate and unaffected by Bacillus Calmette-Guérin (BCG) vaccination (2–4).

QFT is an interferon-gamma (IFNγ) release assay, commonly known as an IGRA, and measures the cell-mediated immune response to specific TB antigens in whole blood. Patients may be tested in a single patient visit, with objective results, eliminating the need for two-step testing (1). The test has proven performance in immunosuppressed patients (5–8).

By reducing false positive results seen with TST, QFT reduces the costs associated with unnecessary chest X-rays, chemoprophylaxis, toxic side effects, lost productivity, and labor costs resulting from two-step TST testing. Studies show that QFT can reduce the cost of maintaining healthcare worker screening programs by up to 32% (10).

Principle
QFT uses a peptide cocktail simulating ESAT-6, CFP-10, and TB7.7(p4) proteins to stimulate cells in heparinized whole blood. Detection of IFNγ by ELISA is used to identify in vitro responses to these peptide antigens, which are associated with M. tuberculosis infection (figure QuantiFERON-TB Gold interpretation flowchart 1 and QuantiFERON-TB interpretation flowchart 2).
 
Table 1. QuantiFERON-TB Gold test results
QFT result Likelihood of TB infection
Positive Likely
Negative NOT likely
Indeterminate Results are indeterminate for TB antigen responsiveness

When TB infection can neither be excluded nor confirmed (Indeterminate QFT result), further evaluations are required. Table adapted from QFT Package Insert (1).

Procedure
The QFT assay is a straightforward laboratory test that involves the following steps:
  1. Collect whole blood in specialized QFT blood collection tubes.
  2. Incubate for 16 to 24 hours at 37°C.
  3. Detect released IFNγ in harvested plasma by ELISA.
  4. Analyze results using QFT Analysis Software.

QFT has 3 blood collection tubes (Nil, TB Antigen, and Mitogen) — 1 ml of whole blood should be collected into each tube.

Applications

QFT can be used in many clinical and public health settings, including screening for healthcare workers, immigrants, military personnel, those in correctional facilities, and homeless individuals.

    QFT can also be used in at-risk populations, such as:

    • People taking certain medications (e.g., TNF alpha inhibitors)
    • Patients with weakened immune systems
    • Elderly patients 

    You are not authorized to download the resource

    QIAGEN Websites (1)
    Learn about QuantiFERON-TB Gold products, read translations of package inserts for international customers, and more.
    fragment fix placeholder